Many epidemiology studies have indicated that polymorphisms in ICAM-1 are associated with a variety of cancers, but published data are contradictory and inconclusive. Therefore, we conducted the current meta-analysis to elaborate the effects of ICAM-1 polymorphisms (rs5491, rs3093030, rs281432, and rs1799969) on cancer susceptibility.
Background
Cancer is a major public health problem all over the world, and has become one of the primary causes of morbidity and mortality [1] . The epidemiology of cancer is influenced by the aging and growth of the world population and a rise in cancercausing behaviors; therefore, the global burden of cancer is rapidly increasing [1, 2] . The etiology of cancer is complex and is still obscure. Recent research suggests that single-nucleotide polymorphisms (SNPs) in genes play critical roles in cancer development and progression [3] [4] [5] [6] . Among these SNPs, ICAM-1 polymorphisms have been shown to be particularly important.
ICAM-1, a single-chain 76-110 kDa glycoprotein, is a member of the immunoglobulin superfamily, which is involved in cell adhesion and signalling [7] . Studies indicate that ICAM-1 plays an important role in tumorigenesis and tumor progression, specifically by facilitating tumor invasion and metastases [8, 9] . Many case-control studies have demonstrated that ICAM-1 polymorphisms (rs5491, rs3093030, rs281432, and rs1799969) are associated with susceptibility to many cancers, including colorectal cancer [10] , breast cancer [11, 12] , diffuse astrocytoma [13] , prostate cancer [14] , cutaneous malignant melanoma [15] , ovarian cancer [16] , urothelial cell carcinoma [17] , oral cancer [18] , and acute promyelocytic leukanemia (APL) [19] .
In view of the relevance of ICAM-1 polymorphisms (rs5491, rs3093030, rs281432, and rs1799969) in susceptibility to cancer, many studies have been conducted [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] but the results were inconclusive and inconsistent. In 2014, Wang et al. [20] performed a meta-analysis of 14 studies and concluded that ICAM-1 rs5498 polymorphism was associated with cancer susceptibility. In the present study, we aimed to clarify the relationship between other ICAM-1 polymorphisms (rs5491, rs3093030, rs281432, and rs1799969) and cancer susceptibility based on all eligible published case-control studies.
Material and Methods

Literature search strategy
All eligible case-control studies on the relationship between polymorphisms of ICAM-1 (rs5491, rs3093030, rs281432, and rs1799969) and cancer susceptibility up to June 16, 2015 were identified by a systematic literature search in PubMed, Web of Science, and Google Scholar. The search terms were: ("Intercellular adhesion molecule-1" OR"ICAM -1") AND ("cancer" OR "carcinoma" OR "neoplasms") AND ("polymorphism" OR "variant" OR "mutation"). In addition, for each retrieved publication, a manual search for relevant references was also conducted to find additional case-control studies.
Selection criteria
The inclusion criteria were: 1) evaluation of the ICAM-1 polymorphisms and cancer susceptibility, 2) case-control studies, and 3) presenting available information to assess the odds ratio (OR) with 95% confidence interval (CI). Major reasons for exclusion of studies were: 1) no control population, 2) abstracts and reviews, 3) no available genotype frequency, 4) duplication of the previous publication, and 5) non-human studies.
Data extraction
Two investigators (Xiaolong Zhang and Junjie Huang) independently extracted data on ICAM-1 polymorphisms, first author, year of publication, ethnicity of the case-control studies, genotyping methods, source of controls, type of cancer, and genotype number in cancer cases and controls. Any disagreements were resolved by discussion and consensus.
Statistical analysis
We evaluated the association between ICAM-1 polymorphisms and cancer susceptibility by OR and 95% CI. The significance of the pooled OR was determined by the Z-test and P<0.05 was considered statistically significant. A total of 4 genetic models were selected: allele contrasts, additive genetic model, recessive genetic model, and dominant genetic model separately. Heterogeneity was detected by the c 2 -based Q statistic test to assess the heterogeneity within the case-control studies [21] . When there was heterogeneity (p<0.10, I 2 >50%), the randomeffects model was used to calculate the pooled ORs [22] ; otherwise, the fixed-effects model was used [23] . P values of the HWE for control groups were tested by c 2 test. Stratification analyses of cancer type, genotyping method, and source of control were conducted. Sensitivity analyses were further performed to calculate the stability of the results by removing each case-control study from the enrolled pooled data to detect the influence of the respective data set on the pooled ORs. To examine the potential publication bias, Begg's funnel plot and Egger's regression test were used [24, 25] . The STATA 12.0 (Stata Corporation, College Station, TX) was used to conduct all statistical analyses.
Quality evaluation
The study quality was assessed independently by Xiaolong Zhang and Junjie Huang by referring to the Newcastle-Ottawa scale (NOS), which examines the quality of non-randomized studies by the selection of participants, comparability of groups, and exposure assessment. Any disagreements were resolved by discussion and consensus.
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Results
Study characteristics
After a systematic literature search and selection based on the inclusion criteria, 140 publications were considered for eligibility. However, among these eligible articles, 115 are disqualified because they were not about polymorphisms, were not cancer studies, or they were reviews or letters. Of the remaining 25 publications, 7 were based on case-only design, 5 were not polymorphism studies, and 4 were not about susceptibility to cancer. As a result, 9 publications with 14 case-control studies including 4608 cancer cases and 4913 controls were included in the present meta-analysis. We present a flow chart of the study screening process in Figure 1 . The characteristics of enrolled studies are presented in Table 1 [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Eight studies were conducted in people of Asian ethnicity, 6 studies were conducted in people of white ethnicity, and only 1 study 
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License was conducted in people of African ethnicity. In addition, there were 10 studies done by PCR, 4 performed by TaqMan, and only 1 conducted by PCR-RFLP. The control groups consisted of 10 population-based studies and 5 hospital-based studies. Of these included studies, 3 reported urothelial cell carcinoma and 3 reported oral cancer. Two studies were on breast cancer, 2 were on APL, and 2 were on ovarian cancer. Prostate cancer, cutaneous melanoma, and colorectal cancer were also mentioned in other studies. Only one case-control studies deviated from HWE [15] .
Meta-analysis
The results of the meta-analysis for the association between ICAM-1 polymorphisms (rs5491, rs3093030, rs281432, and rs1799969) and susceptibility to cancer are presented in 
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According to the present analysis, we discovered that ICAM-1 rs1799969 polymorphism was significantly associated with overall cancer susceptibility ( Figure 2B ; CC+CT vs. TT: OR=1.812, 95%CI=1.373-2.391, p=0.284, Figure 2C ). Nevertheless, no relevance was identified between other ICAM-1 polymorphisms (Table 2A, rs5491; Table 2B, rs3093030;  Table 2D , rs281432) and overall cancer susceptibility.
In stratified analysis of the source of controls, an increased susceptibility of the population-based group in rs1799969 polymorphism was found in 3 genetic models ( Figure 3 ) in the stratification analysis by ethnicity.
Sensitivity analyses and publication bias
Sensitivity analysis confirmed the pooled results (data not shown). Egger's test and Begg's funnel plot were performed to examine the publication bias risk and we found no publication bias (Figure 4A-4D) .
Additionally, the quality of the enrolled studies is shown in Table 3 .
Discussion
ICAM-1, a cell adhesion molecule with a key role in inflammation and immune surveillance, has been implicated in carcinogenesis by facilitating instability of the tumor environment [26, 27] . In 2014, Wang et al. conducted a meta-analysis and concluded that ICAM-1 rs5498 polymorphism was associated with cancer susceptibility. However, the association between cancer susceptibility and other polymorphisms of ICAM-1 (rs5491, rs3093030, rs281432, and rs1799969) remained unclear. Recently, Dore et al. [19] [10, 12, 15] . In addition, several publications (casecontrol studies) indicated that ICAM-1 polymorphisms (rs5491, rs3093030, and rs281432) were also involved in tumorigenesis and tumor progression. However, the conclusions were inconclusive because of the limited number of relevant published reports. Therefore, we performed the present meta-analysis.
We aimed to comprehensively define the association between ICAM-1 polymorphisms (rs5491, rs3093030, rs281432, and rs1799969) and cancer susceptibility in a total of 9 publications, including 14 case-control studies with 4608 cases and 4913 controls. We demonstrated that polymorphism rs1799969 of ICAM-1 was significantly associated with cancer susceptibility. Moreover, in the stratified analysis, significant cancer susceptibility in population-based and Asian groups was identified for rs1799969 and rs3093030, respectively. It was well-established that hospital-based studies may have selection bias; the controls may only represent a poorly-defined reference population rather than the general population or the population of interest, especially when the genotypes examined are relevant to disease-related factors that the hospital-based controls may have been exposed to. The selection of appropriate and representative controls is of great importance in reducing biases in polymorphism association studies. Therefore, we conducted subgroup analysis by source of control and found that the source of control did not influence our conclusions.
Although we conducted a comprehensive retrieval of all eligible studies, several limitations of this meta-analysis should be acknowledged. Firstly, the number of currently available case-control studies enrolled in our study was small and we could not achieve definitive results. Secondly, lack of detailed data on individuals limited the precision of our analysis of adjusted estimates involving other factors such as age and sex. Thirdly, only 1 study discussed the genetic predisposition of every ICAM-1 polymorphism to each cancer, and we could not evaluate the effects of a single polymorphism of ICAM-1 on a specific cancer because eligible case-control studies were insufficient for pooled analysis. Finally, the effect of ICAM-1 polymorphisms on cancer susceptibility might be affected by complex factors, such as histological types of cancer and matching criteria.
